Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C J Turtle

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Current Drug Targets|January 24, 2004
Dendritic cells in tumor immunology and immunotherapyC J Turtle, D N J Hart
Australian and New Zealand Journal of Medicine|January 12, 2000
Q-fever associated with splenic infarction and an anti-cardiolipin antibodyC J Turtle, L A Coyle, G Kotsiou
Clinical Pharmacology and Therapeutics|May 13, 2016
CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignanciesC J Turtle, S R Riddell, D G Maloney
Cytotherapy|June 19, 2004
DC in multiple myeloma immunotherapyC J Turtle, R D Brown, D E Joshua, et al.
Australian and New Zealand Journal of Medicine|May 26, 1999
Severe adverse reaction to high dose epirubicin and cyclophosphamide for poor prognosis breast cancerC J Turtle, D M Keefe, D Bell, et al.
Cytotherapy|June 19, 2004
The immune response to breast cancer, and the case for DC immunotherapyC P Allan, C J Turtle, P N Mainwaring, et al.
Leukemia|September 16, 2015
Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivoD Sommermeyer, M Hudecek, P L Kosasih, et al.
British Journal of Haematology|August 30, 2008
Practical blood dendritic cell vaccination for immunotherapy of multiple myelomaF Vari, D J Munster, J L Hsu, et al.
Nature Communications|September 27, 2024
Histone marks identify novel transcription factors that parse CAR-T subset-of-origin, clinical potential and expansionS Fiorenza, Y Zheng, J Purushe, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Current Drug Targets|January 24, 2004
Dendritic cells in tumor immunology and immunotherapyC J Turtle, D N J Hart
Australian and New Zealand Journal of Medicine|January 12, 2000
Q-fever associated with splenic infarction and an anti-cardiolipin antibodyC J Turtle, L A Coyle, G Kotsiou
Clinical Pharmacology and Therapeutics|May 13, 2016
CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignanciesC J Turtle, S R Riddell, D G Maloney
Cytotherapy|June 19, 2004
DC in multiple myeloma immunotherapyC J Turtle, R D Brown, D E Joshua, et al.
Australian and New Zealand Journal of Medicine|May 26, 1999
Severe adverse reaction to high dose epirubicin and cyclophosphamide for poor prognosis breast cancerC J Turtle, D M Keefe, D Bell, et al.
Cytotherapy|June 19, 2004
The immune response to breast cancer, and the case for DC immunotherapyC P Allan, C J Turtle, P N Mainwaring, et al.
Leukemia|September 16, 2015
Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivoD Sommermeyer, M Hudecek, P L Kosasih, et al.
British Journal of Haematology|August 30, 2008
Practical blood dendritic cell vaccination for immunotherapy of multiple myelomaF Vari, D J Munster, J L Hsu, et al.
Nature Communications|September 27, 2024
Histone marks identify novel transcription factors that parse CAR-T subset-of-origin, clinical potential and expansionS Fiorenza, Y Zheng, J Purushe, et al.
Pageof 1